Levodopa/Carbidopa Teva (Carbidopa, Levodopa)

Levodopa and Carbidopa, the active ingredients in Levodopa/Carbidopa Teva, are Antiparkinson agents presented as oral tablets for oral use. They are prescribed to manage motor symptoms in patients with Parkinson's disease and related Parkinsonian syndromes.

GNH USA supplies Levodopa/Carbidopa Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa is used in the management of Parkinsonian disorders, improving dopaminergic neurotransmission.

- Parkinson's disease: alleviates bradykinesia, rigidity and tremor. - Parkinsonian syndrome: restores motor function in secondary Parkinsonism. - Rest tremor: reduces amplitude of tremor episodes.

Levodopa/Carbidopa may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Orthostatic hypotension: dizziness upon standing. - Headache: transient cranial discomfort. - Insomnia: difficulty initiating sleep. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Dyskinesia: involuntary, erratic movements. - Psychiatric disturbances: hallucinations, confusion, or depression. - Severe hypotension: marked drop in blood pressure requiring medical attention. - Allergic reactions: rash, pruritus, or angioedema.

When prescribing Levodopa/Carbidopa, clinicians should consider several precautionary measures.

- Dyskinesia monitoring: watch for involuntary movements. - Cardiovascular assessment: check for orthostatic hypotension. - Abrupt discontinuation: avoid sudden stop to prevent withdrawal effects. - Hepatic impairment: use with caution in liver disease. - Pregnancy safety: unknown, weigh risks and benefits before use. - Store at ambient temperature: keep in original container, protect from moisture.

Levodopa/Carbidopa interacts with several medicines; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics (dopamine antagonists): may diminish therapeutic effect. - Pyridoxine (vitamin B6) high doses: reduces levodopa conversion. - High‑protein meals: interfere with levodopa absorption.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive hypotensive effect. - SSRIs and other serotonergic drugs: monitor for serotonin syndrome. - Other dopaminergic agents: may increase dyskinesia risk. - Iron or calcium supplements: may decrease levodopa bioavailability.